Entity

Time filter

Source Type

Östermalm, Sweden

The invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof that (a) binds (i) wild-type A 42/40 protofibril comprising N-terminal truncated A forms and (ii) A 42/40 Arc protofibril comprising N-terminal truncated A forms and (b) has no or little cross-reactivity to A 42/40 monomers. The invention further relates to a method of using such an antibody to treat Alzheimers disease.


Patent
BioArctic Neuroscience AB and Eisai R&D Management Co. | Date: 2015-07-08

The present invention relates to the amyloid beta peptide (A) and more specifically to antibodies binding to A protofibrils and their use in therapy and/or prophylactic treatment of Alzheimers disease and other disorders associated with A protein aggregation. Further the invention may relate to diagnosis of such diseases as well as monitoring of disease progression by use of the antibodies of the invention. Further, the invention may relate to veterinary use of the antibodies of the invention.


Patent
BioArctic Neuroscience AB | Date: 2012-12-03

A spinal cord device comprises a body formed of a biocompatible, biodegradable matrix. The body includes proximal, cranial and distal, caudal surfaces for connection to two ends of an injured spinal cord after removal of an injured section and has through channels with openings in the cranial and caudal surfaces for connection of descending motor pathways and ascending sensory pathways. The device has a transversal diameter (D


The invention pertains to a method of measuring A protofibrils in a sample. The method includes the steps of (a) providing a labeled monoclonal antibody or fragment thereof that binds wildtype A 42/40 protofibril and A42/40 Arc protofibril and has no or little cross-reactivity to A 42/40 monomers with an agent that generates a measurable signal, (b) contacting said labeled antibody or fragment thereof with the fluid or tissue having or suspected of comprising A protofibrils, and (c) measuring the amount of protofibrils bound to the antibody by measuring the signal generated by the agent.


The invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof that (a) binds (i) wild-type A 42/40 protofibril comprising N-terminal truncated A forms and (ii) A 42/40 Arc protofibril comprising N-terminal truncated A forms and (b) has no or little cross-reactivity to A 42/40 monomers. The invention further relates to a method of using such an antibody to treat Alzheimers disease.

Discover hidden collaborations